eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with...
12 insider purchases on record · latest filing 2022-10-06.
Insiders have also filed 114 sale transactions at EFTR.